Optimizing the Risk-benefit Conversation with Inflammatory Bowel Disease Patients

Abstract

Key Takeaways:

Contextualize Treatment Options Against the Risk of No Treatment:

A primary driver of therapeutic hesitancy is a disproportionate fear of medication side effects. Clinicians must counter this by clearly articulating the severe and often certain morbidity associated with untreated intestinal inflammation.

Leverage the Safety Profile of Selective Pathways:

The expansion of the therapeutic armamentarium allows for more personalized efficacy and safety considerations. Factor this in when helping patients choose appropriate treatment options (ie. Treatments that will treat extra-intestinal manifestations; treatments with impeccable safety profiles for those patients exceptionally anxious over side effects).

Utilize Structured Communication Models:

Effective communication is the cornerstone of the therapeutic alliance, yet many patients report that treatment discussions are often brief and lack depth. Adopting a structured framework can ensure a collaborative rather than directive process.

Address the Disconnect in Treatment Goals:

There is a significant disconnect between what clinicians measure and what patients experience. While doctors focus on objective markers like fecal calprotectin and endoscopic findings, patients are often most burdened by bowel urgency. Centring the risk-benefit conversation on the restoration of social and professional functioning—rather than just laboratory targets—can meaningfully improve patient satisfaction and long-term treatment adherence.